Darby disposed of 27% of his direct equity stake at prices ranging from $47.24 to $48.54 per share, leaving him with 53,850 shares valued at $2.6 million.
Teva Pharmaceutical Industries (NYSE:TEVA) said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics business, an expanding biosimilars portfolio and a strengthened balance sheet.
Speaking at a Morgan Stanle
RF Industries (NASDAQ:RFIL) reported record fiscal third-quarter revenue of $24 million, up 21% from the prior-year period and 16% sequentially, as higher-value integrated systems and custom cabling offerings contributed to growth and profitability.
Chief Executive Officer Rob Dawson said the quart
SM Energy's stock has doubled in 2025 after its Civitas merger boosted revenue and cash flow, cut debt, and prompted a higher dividend, though risks and integration costs remain.
IREN's AI ambitions are getting a real-world test. See what Horizon 1 changes, what must happen next, and why repeatable execution could matter more than another blockbuster contract.
The Vanguard Morningstar Growth ETF is a great fund for investors who want megacap growth exposure, but it doesn't need to be paired with its S&P 500 counterpart.
Una implementación de Google Analytics 4 puede parecer correcta y, sin embargo, estar tomando decisiones sobre datos incompletos, duplicados o directamente
Intel shares rallied on unconfirmed reports of a 10% CPU price hike amid tight server chip supply, prompting analyst upgrades even as MarketBeat's consensus rating remains a Hold.
The Hain Celestial Group (NASDAQ:HAIN) said it has agreed to sell its international business to private equity firm Aurelius for $323 million in cash, a transaction that would leave the company focused on a streamlined North American portfolio. The company expects the sale to close in its fiscal sec
McKesson (NYSE:MCK) executives said the company’s first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions businesses.
Speaking at the Morgan Stanl
Healthcare continues to experience major changes as consumers become more focused on personalized services, better experiences, and technology-driven solut
One company is returning billions to shareholders while demand for its products continues to accelerate. The other is still years away from making money on the cars it sells.
